65,437 trials
Diabetes Mellitus, Type 2
Primary: Change in Glycated Haemoglobin (HbA1c) — -1.16; -1.18 Percentage (%) of HbA1c — p=<0.0001
Hypertension
Primary: Changes in Gray Matter Intracranial Pulsatility — -0.09; 0.02 mm/cardiac cycle
Major Depressive Disorder
Primary: Change in Snaith-Hamilton Pleasure Scale (SHAPS) — 38.4; 33.2; 27.2; 26.2 units on a scale
Cigarette Smoking
Primary: Nicotine/Tobacco Products Substitution Intercept — 16.4; 94.2; 47.8; 56.0 Mg of Nicotine purchased
Acute Kidney Injury
Primary: Renal Function — .46; .75; 4.26; 2.80 mL/min/1.73m^2 — p=>0.05
NLRC4-MAS · XIAP Deficiency
Primary: Prevention of Flares — 2.71; NA Weeks
Intervention Engagement and Retention
Primary: Number of Participants Attending at Least 50% of Sessions — 8; 6; 1; 4 Participants
Lung Cancer, Nonsmall Cell
Primary: Data on Whole-body Pharmacokinetics of [18F]F-AraG Physiologic Uptake in Various Healthy Tissues — 0.31; 4.36; 0.04; 32.88 SUV
Pediatric Oncology · Quality of Life
Primary: SSPedi (Symptom Screening in Pediatrics) Total Scores — 13.2; 13.1; 10.2; 12.7 score on a scale
HIV Infections
Primary: Mean Change (Percent) in Body Weight (kg) From Entry to Week 48 — -0.47; -2.73; -1.84 relative change % — p=0.23
Solid Tumor · Lymphoma
Primary: Number of Participants Who Experienced Dose-Limiting Toxicities (DLTs) — 0; 0; 0; 0 Participants
Cheilitis, Angular · Postoperative Complications · Adenotonsillar Hypertrophy
Primary: Incidence of Angular Cheilitis — 5; 22; 46; 28 Participants
Human Immunodeficiency Virus
Primary: Change in Bone Mineral Density (BMD) at Lumbar Spine and Left Hip From Baseline to Week 48 — 0.010; 0.013 g/cm² — p=0.0239
Chronic Hand Eczema
Primary: Number of Participants With IGA-CHE Treatment Success at Week 16 — 47; 7 Participants
Depressive Disorder
Primary: Children's Depression Rating Scale - Revised — 36.0; 37.5 score on a scale — p=0.76